HK Stock Market Move | BOAN BIOTECH(06955) rose by over 3%. The Boaoyouping Dexralose peptide injection has been approved for listing in China. Commercialization will be conducted in partnership with Shangyi Holdings.

BOAN BIOTECH (06955) rose more than 3%, as of the publishing of this article, it had risen by 2.61% to 18.88 Hong Kong dollars, with a trading volume of 3.13 billion Hong Kong dollars. On the news front, on August 8, BOAN BIOTECH announced that its independently developed Bopyong (dulaglutide injection) has obtained approval from the National Medical Products Administration for listing, used for blood sugar control in adult type 2 diabetes patients. This product is the world's first and currently only approved biosimilar to Trulicity (English trade name: Trulicity), with no other domestically produced dulaglutide injection entering the Biologics License Application (BLA) stage in China. The commercialization of Bopyong in mainland China is being carried out through a partnership between the company and ShangPharma Holdings Limited (ShangPharma Holdings). As a multi-peptide-Fc fusion protein, dulaglutide is highly complex in terms of process complexity, making the pharmaceutical (CMC) development of biosimilars difficult. The company has accumulated rich technical experience in CMC, and its advanced process development platform has shown strong technical advantages in controlling the truncation, hydroxylation and oxidation, acetylation, and succinoylation of fusion protein molecules at the GLP-1 end; at the same time, its efficient analytical platform has developed innovative methods for controlling the above key quality attributes, empowering process development and comparability analysis through comprehensive quality control strategies, successfully overcoming the CMC technical challenges and leading to Bopyong being the first to be approved for listing. Outside of the Chinese market, Bopyong has also been approved to conduct clinical trials in the United States.